80 results about "Pancreas Inflammation" patented technology

The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and / or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and / or LXRβ agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis / fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired / improvable cognitive function.

Invented is a method of inhibiting the activity / function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephrtitis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The invention provides a method for intelligent assisted identification for diseases like pancreatic cancer and pancreatitis. The method comprises the steps of performing reading and normalization operation on medical image data of pancreas to obtain normalization images; performing denoising, registration and image fusion on the normalization images to obtain multi-mode fusion images; selecting areas of interest from images in which pancreas structures are displayed clearly and mapping the areas of interest to the other images and at the same time storing the areas of interest in a natural image format which can be recognized by a following classification network; according to the selected areas of interest, extracting, classifying and fusing features of the multi-mode fusion images and building basic classification network models for the fused features; distinguishing classification results of the basic classification networks to obtain a final classification distinguishing result. The method has great universality; the method is suitable for both clinical practice and scientific research in the field of pancreatic cancer and pancreatitis.

Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephrtitis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof, to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists may be administered to mammals either alone or in combination with NPY Y2 receptor agonists including peptide YY (PYY) (3-36), analogs thereof, and to peptide fragments of PYY(3-36), e.g. PYY(22-36) and PYY(25-36), and analogs thereof, such as to control food intake in mammals, blood pressure, cardiovascular response, libido, circadian rhythm, hyperlipidimia, chronic pancreatitis, and nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The present invention relates to a urea derivative of the formula (1)wherein each symbol is as described in the specification, a pharmaceutically acceptable salt thereof and pharmaceutical use thereof. The compound of the present invention has a C5a receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of diseases or syndromes due to inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis, pancreatitis and the like) due to activation of leukocytes caused by ischemia, trauma, burn, surgical invasion and the like]. In addition, it is useful as an agent for the prophylaxis or treatment of infectious diseases caused by bacteria or virus that invades via a C5a receptor.

A novel form of lipase, namely feline pancreatic lipase (also termed feline classical pancreatic lipase) has an N-terminal amino acid sequence as shown in SEQ ID NO. 1. A method of purifying this lipase includes collecting pancreatic tissue from cats, delipidating the pancreatic tissue to produce a delipidated pancreatic extract, extracting pancreatic lipase from the delipidated pancreatic extract, and eluting the extracted pancreatic lipase through various columns. This lipase can be used for measuring pancreatic lipase immunoreactivity in serum thereby diagnosing pancreatitis in cats. To do so, antiserum against feline pancreatic lipase is prepared, and immunoassays are then performed in serum samples using this antiserum. In the event that increased concentration of pancreatic lipase immunoreactivity above the control range is detected in the serum, the cat might have pancreatitis.

Natural and synthetic compounds having a lactone structure methods for using and making the compounds have been disclosed. The compounds are useful as anti-bacterial, anti-fungal and anti-inflammatory agents, and for treating proliferation disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer. The compounds are also effective for treatment or prevention of inflammatory diseases such as artherosclerosis, lung fibrosis, systemic lupus erythematosus, pancreatitis, sarcoidosis, glomerulitis, and organ transplant rejection. They are also effective for treatment or prevention of bacterial and fungal infections, including treatment of peptic ulcers, gastritis, dyspepsia and gastric cancer, gingivitis and periodontitis.

The present invention relates to novel sulfoxide and bis-sulfoxide compounds, compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Natural and synthetic compounds having a lactone structure methods for using and making the compounds have been disclosed. The compounds are useful as anti-bacterial, anti-fungal and anti-inflammatory agents, and for treating proliferation disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer. The compounds are also effective for treatment or prevention of inflammatory diseases such as atherosclerosis, lung fibrosis, systemic lupus erythematosus, pancreatitis, sarcoidosis, glomerulitis, and organ transplant rejection. They are also effective for treatment or prevention of bacterial and fungal infections, including treatment of peptic ulcers, gastritis, dyspepsia and gastric cancer, gingivitis and periodontitis.

Invented is a method of inhibiting the activity / function of PI3 kinases using thiazolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiazolidinedione derivatives.

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The present application relates to urinary protein markers for chronic pancreatitis and uses thereof. Specifically, this application relates to the use of urine protein markers obtained by using chronic pancreatitis disease models and mass spectrometry analysis in the early diagnosis of human chronic pancreatitis disease and the use of disease course monitoring. The urine protein markers are selected from Igγ‑1 chain C domain, nucleonectin‑2, beta‑2‑microglobulin, interleukin‑4 receptor alpha subunit, phosphoglycerate mutase 1, dipeptidyl peptidase 2, secreted pyrophosphoprotein 24, glycans Core protein, endothelial cell selective adhesion molecule, nestin-2, serum amyloid substance p, nerve cell adhesion molecule 1, etc. In this application, the obtained differential protein in urine provides a non-invasive and convenient option for early diagnosis and subsequent treatment of chronic pancreatitis.

The invention discloses a method for identifying pancreatic cancer by taking microRNA in blood as a marker, relating to the technical field of medical molecular biology. The method comprises the following steps of: manufacturing a standard expression level map of microRNA-21 in the pancreatic cancer, chronic pancreatitis and the blood plasma of a normal person through large sample survey and detection; then contrasting the expression abundance value delta Ct of the microRNA-21 in an unknown blood plasma specimen with the standard expression level map of the microRNA-21; if the expression abundance value is within the range of the microRNA of a pancreatic cancer group, judging to be the pancreatic cancer, and if the expression abundance value is within the range of the chronic pancreatitis or the normal person group, basically ruling out the pancreatic cancer. The invention has the characteristics of convenient detection, high accuracy and the like.

The invention discloses a kit for detecting trypsin and the inhibitor thereof based on platinum nanoclusters. The kit is characterized in that synthesized platinum nanocluster simulated oxidase is utilized to catalyze the color development of the coupling product of 3-Methyl-2-benzothiazolinone hydrazone hydrochloride monohydrate and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline sodium salt;protamine makes platinum nanoclusters aggregate by means of an electrostatic effect, so that the catalytic activity of the nanoclusters is decreased; the protamine is hydrolyzed by trypsin, and so that the trypsin can effectively inhibit the effect of the protamine on the aggregation of the platinum nanoclusters. Therefore, on the basis of solution color change and ultraviolet absorption spectrumfeature change, the kit can be directly used for the determination of the trypsin and the content of the inhibitor of the trypsin. The rapid detection method provided by the invention does not need complicated chemical modification or signal labeling, has strong anti-interference capacity, can quickly and accurately realize the rapid detection of the trypsin, and is suitable for clinical application, for example the diagnosis of diseases such as pancreatitis.

Invented is a method of inhibiting the activity / function of PI3 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinazoline derivatives.

The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The invention discloses a construction method of a mouse model simulating human acute pancreatitis. Targeting vector plasmids containing PRSS1 genes are constructed and transferred to mouse embryonic stem cells electrically, and the mouse embryonic cells carrying the recombinant PRSS1 genes are obtained; the mouse embryonic cells carrying the recombinant PRSS1 genes are micro-injected into albinistic mouse blastodermal cells, the blastodermal cells receiving injection are transplanted to the uteri of pseudo-pregnant maternal mice, and chimeric mice are obtained after transplanting; male chimeric mice with the chimerism higher than 25% and wild C57BL / 6J female mice are mated, the next generation of mice are bred, and mice carrying PRSS1 genes are screened. The phenotype of the model mouse is greatly identical to the pathogenetic process of human acute pancreatitis, and the specific animal model completely simulating human acute pancreatitis from gene to phenotype is obtained and can be further widely applied to researches on pathopoiesis, pathomechanism and the like of human PRSS1 as well as screening and gene therapy tests of medicines for treating pancreatitis and the like.

The present invention relates to a method of preventing and / or treating pancreatitis in a subject, the method including administering to the subject a therapeutically effective amount of a Galanin antagonist and / or a Galanin receptor antagonist.

The object of the present invention is to provide a compound useful as a renal disease preventive and / or therapeutic agent. The inventors of the present invention investigated compounds having a trypsin inhibitory activity, verified that a guanidinobenzoic acid compound has a trypsin inhibitory activity, and achieved the present invention. This guanidinobenzoic acid compound can be used as: a renal disease preventive and / or therapeutic agent that serves as a substitute drug in a low-protein diet regimen; and a preventive and / or therapeutic agent against diseases to which trypsin contributes such as pancreatitis, reflux esophagitis, hepatic encephalopathy, and influenza.

Invented is a method of inhibiting the activity / function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

The invention discloses application of berberine or other pharmaceutically acceptable salts in preparing a M3 receptor selective inhibitor medicine. The medicine is used for treating acute pancreatitis, lung cancers and colon cancers, self-immunity sialadenitis, asthma, respiratory tract inflammation, lung diseases and cardiovascular diseases, relieving panic, or treating excessive activity of bladders, and is used for inhibiting the enhancing of Ca<2+> signals in pancreatic acinar cells caused by M3 receptor-mediated acetyl choline and L-arginine.

The invention provides a construction method of an acute pancreatitis animal model. According to the construction method, high-fat feed and alcohol are used for jointly inducing animals to form acute pancreatitis. Obesity caused by high-fat feed and alcohol can synergistically cause pathological damage to pancreas of mice, local inflammatory response of pancreas and inflammatory response of lungs and the whole body. In a basic obesity state, the morbidity condition of a large amount of alcohol drinking of the animal model is closer to human morbidity, pancreatic injury is obvious and accompanied by multiple organ dysfunction syndromes, and the animal model accords with the clinical characteristic that obese acute pancreatitis patients are prone to severe illness. The animal model is simple in modeling method, good in repeatability and high in clinical correlation, the model can be used for studying the pathogenesis of obesity and alcohol-related acute pancreatitis, and an important basis is provided for screening treatment targets and studying medical transformation.